Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.44−0.15 (-4.18%)
Close on Nov 13, 2026Market cap $13.93MP/E 0.1Yield –
Kyntra Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Kyntra Bio's profit margin for the twelve months ending Jun 30, 2026 was 3967.8%. For fiscal 2025 it was 2848.6%, against -160.6% the year before. The highest annual figure on record is 2848.6% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2848.6% | +3009.3 |
| FY2024 | Dec 31, 2024 | -160.6% | +446.7 |
| FY2023 | Dec 31, 2023 | -607.3% | −398.6 |
| FY2022 | Dec 31, 2022 | -208.7% | −85.4 |
| FY2021 | Dec 31, 2021 | -123.3% | −15.9 |
| FY2020 | Dec 31, 2020 | -107.4% | −77.4 |
| FY2019 | Dec 31, 2019 | -30.0% | +10.6 |
| FY2018 | Dec 31, 2018 | -40.6% | +51.7 |
| FY2017 | Dec 31, 2017 | -92.3% | −60.6 |
| FY2016 | Dec 31, 2016 | -31.7% | +15.7 |
| FY2015 | Dec 31, 2015 | -47.4% | −4.2 |
| FY2014 | Dec 31, 2014 | -43.2% | −28.6 |
| FY2013 | Dec 31, 2013 | -14.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -406.6% | −575.9 |
| Q4 FY2025 | Dec 31, 2025 | -1113.5% | −1687.1 |
| Q3 FY2025 | Sep 30, 2025 | 18646.5% | +32535.9 |
| Q2 FY2025 | Jun 30, 2025 | -564.0% | +993.5 |
| Q1 FY2025 | Mar 31, 2025 | 169.4% | +299.2 |
| Q4 FY2024 | Dec 31, 2024 | 573.6% | +780.8 |
| Q3 FY2024 | Sep 30, 2024 | -13889.4% | −13730.9 |
| Q2 FY2024 | Jun 30, 2024 | -1557.5% | −1359.7 |
| Q1 FY2024 | Mar 31, 2024 | -129.8% | +82.3 |
| Q4 FY2023 | Dec 31, 2023 | -207.2% | −14.7 |
| Q3 FY2023 | Sep 30, 2023 | -158.5% | +424.0 |
| Q2 FY2023 | Jun 30, 2023 | -197.8% | +45.8 |
| Q1 FY2023 | Mar 31, 2023 | -212.1% | −108.2 |
| Q4 FY2022 | Dec 31, 2022 | -192.6% | +617.9 |
| Q3 FY2022 | Sep 30, 2022 | -582.5% | −614.4 |
| Q2 FY2022 | Jun 30, 2022 | -243.7% | +306.3 |
| Q1 FY2022 | Mar 31, 2022 | -103.9% | +82.8 |
| Q4 FY2021 | Dec 31, 2021 | -810.5% | −720.3 |
| Q3 FY2021 | Sep 30, 2021 | 31.9% | −43.0 |
| Q2 FY2021 | Jun 30, 2021 | -549.9% | −351.0 |
| Q1 FY2021 | Mar 31, 2021 | -186.7% | +134.4 |
| Q4 FY2020 | Dec 31, 2020 | -90.2% | +1140.3 |
| Q3 FY2020 | Sep 30, 2020 | 75.0% | +224.0 |
| Q2 FY2020 | Jun 30, 2020 | -198.9% | −259.5 |
| Q1 FY2020 | Mar 31, 2020 | -321.1% | −130.8 |
| Q4 FY2019 | Dec 31, 2019 | -1230.5% | −1249.9 |
| Q3 FY2019 | Sep 30, 2019 | -149.0% | −2.4 |
| Q2 FY2019 | Jun 30, 2019 | 60.6% | +113.8 |
| Q1 FY2019 | Mar 31, 2019 | -190.3% | −60.6 |
| Q4 FY2018 | Dec 31, 2018 | 19.4% | +129.7 |
| Q3 FY2018 | Sep 30, 2018 | -146.6% | −86.3 |
| Q2 FY2018 | Jun 30, 2018 | -53.3% | +52.1 |
| Q1 FY2018 | Mar 31, 2018 | -129.7% | −25.7 |
| Q4 FY2017 | Dec 31, 2017 | -110.3% | −24.7 |
| Q3 FY2017 | Sep 30, 2017 | -60.3% | +19.9 |
| Q2 FY2017 | Jun 30, 2017 | -105.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -104.0% | – |
| Q4 FY2016 | Dec 31, 2016 | -85.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -80.2% | – |
See a number that looks wrong?